A 28-year-old female patient presented with a complaint of gingival hyperplasia (GH). The patient has diagnosed with chronic renal failure due to focal segmental glomerulosclerosis. She had a renal transplant eight months before admission to our hospital. The patient was using tacrolimus (TcR) 9 g/day, mycophenolate mofetil 720 mg/day, prednisolone 5 mg/day, lansoprazol 40 mg/day. She did not use nifedipine or phenytoin. Physical examination revealed GH ([Fig. 1](#F1){ref-type="fig"}), but there were no other pathologies. General systemic examination and laboratory tests were normal. The blood TcR level was 11 ng/ml (normal range: 5--20 ng/ml). TcR was interrupted and switched to everolimus. It was observed that GH improved after one month in the outpatient clinic ([Fig. 2](#F2){ref-type="fig"}).
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GH occurs as unwanted side effects of the drugs. These drugs are usually immunosuppressants (such as cyclosporin A (CsA) and TcR), calcium channel blockers (nifedipine) and anticonvulsants (phenytoin) \[[@ref1]\]. CsA-induced GH was found more frequently than TcR. There are even studies showing that TcR does not cause GH alone \[[@ref2], [@ref3]\]. When CsA-induced GH is developed, it is shown that GH is reduced if CsA is replaced by TcR \[[@ref4]\]. In our case, TcR-induced GH was switched to everolimus, and GH regressed.

**Informed Consent:** Written informed consent was obtained from the patient for the publication of the case report and the accompanying images.
